Pediatric Opioid Development Faces Grim Outlook After Advisory Cmte.

Panelists appeared to have more questions than answers as the common cliché of 'more research is needed' dominated the two-day meeting.

More from US FDA Performance Tracker

More from Regulatory Trackers